Novartis India Limited (BOM:500672)
India
· Delayed Price · Currency is INR 930.45
+0.65 (0.07%)
At close: Mar 6, 2026
Novartis India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3,477 | 3,563 | 3,351 | 3,787 | 3,999 | 3,814 | Upgrade
|
| Revenue | 3,477 | 3,563 | 3,351 | 3,787 | 3,999 | 3,814 | Upgrade
|
| Revenue Growth (YoY) | -1.67% | 6.33% | -11.53% | -5.28% | 4.86% | -12.98% | Upgrade
|
| Cost of Revenue | 1,955 | 2,028 | 2,000 | 2,017 | 1,782 | 1,467 | Upgrade
|
| Gross Profit | 1,522 | 1,535 | 1,351 | 1,771 | 2,217 | 2,346 | Upgrade
|
| Selling, General & Admin | 223.1 | 211.3 | 250.1 | 419.2 | 1,097 | 1,187 | Upgrade
|
| Other Operating Expenses | 378.4 | 407.8 | 443.9 | 686.2 | 789.3 | 868.7 | Upgrade
|
| Operating Expenses | 619.5 | 639.3 | 721.8 | 1,170 | 1,979 | 2,177 | Upgrade
|
| Operating Income | 902.2 | 895.2 | 629.2 | 600.8 | 237.7 | 168.7 | Upgrade
|
| Interest Expense | -13.1 | -7.7 | -14.9 | -17.5 | -48.3 | -76.8 | Upgrade
|
| Interest & Investment Income | 408.8 | 408.8 | 551.9 | 543.6 | 209.6 | 241.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.9 | -2.9 | -2.7 | -10.6 | 1.4 | -1.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -15 | 9.7 | 6 | 8.6 | 4.8 | 22.2 | Upgrade
|
| EBT Excluding Unusual Items | 1,280 | 1,303 | 1,170 | 1,125 | 405.2 | 354.4 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -496.4 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.1 | 1.1 | 32.1 | 28.9 | -1.4 | 45.5 | Upgrade
|
| Other Unusual Items | - | - | 26.8 | - | 54.4 | - | Upgrade
|
| Pretax Income | 1,334 | 1,304 | 1,228 | 1,154 | -38.2 | 400.4 | Upgrade
|
| Income Tax Expense | 361.8 | 295.2 | 376.5 | 120.2 | -1 | 191.4 | Upgrade
|
| Earnings From Continuing Operations | 972.3 | 1,009 | 851.9 | 1,034 | -37.2 | 209 | Upgrade
|
| Net Income | 972.3 | 1,009 | 851.9 | 1,034 | -37.2 | 209 | Upgrade
|
| Net Income to Common | 972.3 | 1,009 | 851.9 | 1,034 | -37.2 | 209 | Upgrade
|
| Net Income Growth | 12.69% | 18.44% | -17.58% | - | - | 107.34% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Change (YoY) | 0.01% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 39.38 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | Upgrade
|
| EPS (Diluted) | 39.38 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | Upgrade
|
| EPS Growth | 12.68% | 18.44% | -17.58% | - | - | 107.34% | Upgrade
|
| Free Cash Flow | - | 745.7 | 1,134 | 444.9 | 381.7 | -693 | Upgrade
|
| Free Cash Flow Per Share | - | 30.20 | 45.93 | 18.02 | 15.46 | -28.07 | Upgrade
|
| Dividend Per Share | - | 25.000 | 25.000 | 10.000 | 10.000 | 10.000 | Upgrade
|
| Dividend Growth | - | - | 150.00% | - | - | - | Upgrade
|
| Gross Margin | 43.77% | 43.07% | 40.32% | 46.75% | 55.44% | 61.52% | Upgrade
|
| Operating Margin | 25.95% | 25.13% | 18.78% | 15.86% | 5.94% | 4.42% | Upgrade
|
| Profit Margin | 27.97% | 28.32% | 25.42% | 27.29% | -0.93% | 5.48% | Upgrade
|
| Free Cash Flow Margin | - | 20.93% | 33.84% | 11.75% | 9.55% | -18.17% | Upgrade
|
| EBITDA | 909.08 | 899.9 | 631 | 618.4 | 256.5 | 199.9 | Upgrade
|
| EBITDA Margin | 26.15% | 25.26% | 18.83% | 16.33% | 6.42% | 5.24% | Upgrade
|
| D&A For EBITDA | 6.88 | 4.7 | 1.8 | 17.6 | 18.8 | 31.2 | Upgrade
|
| EBIT | 902.2 | 895.2 | 629.2 | 600.8 | 237.7 | 168.7 | Upgrade
|
| EBIT Margin | 25.95% | 25.13% | 18.78% | 15.86% | 5.94% | 4.42% | Upgrade
|
| Effective Tax Rate | 27.12% | 22.63% | 30.65% | 10.42% | - | 47.80% | Upgrade
|
| Revenue as Reported | 3,871 | 3,982 | 3,968 | 4,369 | 4,331 | 4,144 | Upgrade
|
| Advertising Expenses | - | 23.4 | 19.4 | 61 | 74.6 | 98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.